As Eisai, Biogen plot a course to accelerated approvals for Alzheimer’s drug, a mob of skeptics are waiting to decipher hard numbers
Welcome to the big catalyst of Q3.
Eisai and Biogen won’t reveal their data from a mid-stage study of BAN2401 in Alzheimer’s disease until tomorrow …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
